IRWD · Ironwood Pharmaceuticals Inc · Webcasts, Transcripts & Audio
$4.72
-0.06 (-1.34%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Market Cap
$767.33M
Shares
165.55M
Volume · Nov 19
912.12K
Avg daily vol (3M)
2.1M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Ironwood Pharmaceuticals Inc Webcasts
Earnings calls, investor updates, investor days and conferences for Ironwood Pharmaceuticals Inc (IRWD), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Earnings call
FY26 · Q3
2026-11-05
Ironwood Pharmaceuticals Inc (IRWD) Q3 2026 Earnings Call Transcript
Confident tone
Linzess sales growth and guidance raise
Apraglutide clinical development
Commercial access and pricing
Revenue
$133.04M
▲ 9% YoY Diluted EPS
$0.36
▲ 56.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-10
Ironwood Pharmaceuticals Inc (IRWD) September 10, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-06
Ironwood Pharmaceuticals Inc (IRWD) Q2 2026 Earnings Call
Revenue
$113.04M
▲ 32.6% YoY Diluted EPS
$0.31
▲ 121.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-04
Ironwood Pharmaceuticals Inc (IRWD) June 4, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Ironwood Pharmaceuticals Inc (IRWD) Q1 2026 Earnings Call Transcript
Confident tone
Apraglutide / SBS-IF opportunity
Linzess commercial performance
Pricing and gross-to-net dynamics
Revenue
$106.51M
▲ 158.9% YoY Diluted EPS
$0.24
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-25
Ironwood Pharmaceuticals Inc (IRWD) Q4 2025 Earnings Call Transcript
Confident tone
LINZESS commercial performance and market leadership
Aproglutide STARS II confirmatory Phase III trial
2026 financial guidance and EBITDA growth
Revenue
$47.71M
▼ 47.3% YoY Diluted EPS
$-0.01
▼ 200% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q4
2025-02-27
Ironwood Pharmaceuticals Inc (IRWD) Q4 2024 Earnings Call Transcript
Positive tone
Short bowel syndrome commercial opportunity
Apraglutide NDA progress
LINZESS franchise
Revenue
$90.55M
▼ 23% YoY Diluted EPS
$0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Ironwood Pharmaceuticals Inc (IRWD) Q3 2024 Earnings Call Transcript
Positive tone
LINZESS commercial performance
Apraglutide NDA and launch
Profit and cash flow maximization
Revenue
$91.59M
▼ 19.5% YoY Diluted EPS
$0.02
▼ 77.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Ironwood Pharmaceuticals Inc (IRWD) Q2 2024 Earnings Call Transcript
Positive tone
LINZESS prescription demand
Apraglutide NDA submission
Apraglutide clinical profile and STARS Phase 3
Revenue
$94.40M
▼ 12.1% YoY Diluted EPS
$-0.01
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Ironwood Pharmaceuticals Inc (IRWD) Q1 2024 Earnings Call Transcript
Confident tone
Apraglutide Phase III STARS results
LINZESS commercial performance
2024 financial guidance and one-time adjustment
Revenue
$74.88M
▼ 28% YoY Diluted EPS
$-0.03
▼ 112% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-15
Ironwood Pharmaceuticals Inc (IRWD) Q4 2023 Earnings Call Transcript
Confident tone
Apraglutide / STARS Phase 3 in short bowel syndrome
LINZESS commercial performance
Pipeline catalysts and upcoming data readouts
Revenue
$117.55M
▲ 9.7% YoY Diluted EPS
$-0.01
▼ 103.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-09
Ironwood Pharmaceuticals Inc (IRWD) Q3 2023 Earnings Call Transcript
Revenue
$113.74M
▲ 4.7% YoY Diluted EPS
$0.09
▼ 67.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Ironwood Pharmaceuticals Inc (IRWD) Q2 2023 Earnings Call Transcript
Revenue
$107.38M
▲ 10.4% YoY Diluted EPS
$-6.84
▼ 3357.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-22
Ironwood Pharmaceuticals Inc (IRWD) Q1 2023 Earnings Call Transcript
Revenue
$104.06M
▲ 6.7% YoY Diluted EPS
$0.25
▲ 19% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-02-16
Ironwood Pharmaceuticals Inc (IRWD) Q4 2022 Earnings Call Transcript
Revenue
$107.20M
▼ 8.5% YoY Diluted EPS
$0.27
▲ 8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Ironwood Pharmaceuticals Inc (IRWD) Q3 2022 Earnings Call Transcript
Revenue
$108.64M
▲ 4.7% YoY Diluted EPS
$0.28
▼ 17.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Ironwood Pharmaceuticals Inc (IRWD) Q2 2022 Earnings Call Transcript
Revenue
$97.23M
▼ 6.5% YoY Diluted EPS
$0.21
▼ 91.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Ironwood Pharmaceuticals Inc (IRWD) Q1 2022 Earnings Call Transcript
Revenue
$97.53M
▲ 9.8% YoY Diluted EPS
$0.21
▼ 16% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-02-17
Ironwood Pharmaceuticals Inc (IRWD) Q4 2021 Earnings Call Transcript
Revenue
$117.13M
▲ 0.4% YoY Diluted EPS
$0.25
▼ 7.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Ironwood Pharmaceuticals Inc (IRWD) Q3 2021 Earnings Call Transcript
Revenue
$103.75M
▲ 0.3% YoY Diluted EPS
$0.34
▲ 61.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Ironwood Pharmaceuticals Inc (IRWD) Q2 2021 Earnings Call Transcript
Revenue
$104.03M
▲ 16.3% YoY Diluted EPS
$2.39
▲ 1393.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Ironwood Pharmaceuticals Inc (IRWD) Q1 2021 Earnings Call Transcript
Revenue
$88.84M
▲ 11.1% YoY Diluted EPS
$0.25
▲ 1150% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-17
Ironwood Pharmaceuticals Inc (IRWD) Q4 2020 Earnings Call Transcript
Revenue
$116.68M
▼ 7.6% YoY Diluted EPS
$0.27
▼ 10% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Ironwood Pharmaceuticals Inc (IRWD) Q3 2020 Earnings Call Transcript
Revenue
$103.47M
▼ 21.1% YoY Diluted EPS
$0.21
▲ 61.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Ironwood Pharmaceuticals Inc (IRWD) Q2 2020 Earnings Call Transcript
Revenue
$89.43M
▼ 12.5% YoY Diluted EPS
$0.16
▲ 100% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Ironwood Pharmaceuticals Inc (IRWD) Q1 2020 Earnings Call Transcript
Revenue
$79.94M
▲ 16.3% YoY Diluted EPS
$0.02
Gross margin
97.2%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Showing 1–26 of 26 webcasts
Key facts
CIK
1446847
CUSIP
46333X108
13F (30d)
243 filings
221 filers
Visit website
Investor relations